Detalhe da pesquisa
1.
Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancer.
J Immunother Cancer
; 11(1)2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36593068
2.
Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors.
Eur J Cancer
; 187: 15-24, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37099945
3.
Mytomicin-C, Metronomic Capecitabine, and Bevacizumab in Patients With Unresectable or Relapsed Pseudomyxoma Peritonei of Appendiceal Origin.
Clin Colorectal Cancer
; 22(4): 450-456.e1, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37657955
4.
Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancer.
Eur J Cancer
; 172: 171-181, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35777274
5.
Circulating Tumor DNA as a Marker of Minimal Residual Disease After Radical Resection of Colorectal Liver Metastases.
JCO Precis Oncol
; 6: e2200244, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36356286
6.
Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers.
J Immunother Cancer
; 10(2)2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35110358